Top Markets
Coin of the day
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Classificação em ações #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Preço da ação
$451.59
Valor de mercado
$114.70B
Variação (1 dia)
-2.36%
Variação (1 ano)
-11.89%
País
US
Negociar Vertex Pharmaceuticals Incorporated (VRTX)

Categoria

Rácio P/E de Vertex Pharmaceuticals Incorporated (VRTX)
Rácio P/E em March 2026 TTM: 30.14
De acordo com os últimos relatórios financeiros e o preço das ações da Vertex Pharmaceuticals Incorporated, o rácio P/E atual (TTM) é 30.14. No final de 2023, a empresa tinha um P/E de 28.97.
Histórico do rácio P/E da Vertex Pharmaceuticals Incorporated de 2000 a 2026
Rácio P/E no final de cada ano
Ano Índice P/E Alterar
2026 (TTM) 30.14 -115.57%
2024 -193.61 -768.33%
2023 28.97 30.12%
2022 22.26 -7.86%
2021 24.16 6.69%
2020 22.65 -52.59%
2019 47.77 137.69%
2018 20.10 -85.80%
2017 141.54 -188.38%
2016 -160.15 194.95%
2015 -54.30 43.69%
2014 -37.79 0.67%
2013 -37.54 -54.76%
2012 -82.97 -136.06%
2011 230.08 -2,573.28%
2010 -9.30 -19.61%
2009 -11.57 24.62%
2008 -9.29 21.26%
2007 -7.66 -62.60%
2006 -20.48 68.70%
2005 -12.14 143.00%
2004 -5.00 23.34%
2003 -4.05 -63.36%
2002 -11.05 -60.02%
2001 -27.65 -77.34%
2000 -122.02 0.00%
Rácio P/E para empresas semelhantes ou concorrentes
Empresa Rácio P/E Diferença do rácio P/E País
10.72 -64.45%
DK
17.03 -43.49%
US
30.44 0.98%
BE
33.07 9.72%
AU
38.30 27.06%
NL
Como interpretar um P/E Ratio?

O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.

Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.

Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.